Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.40 |
| ▸ | PDE4A | P27815 | 8/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.39 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 7/20 | 0.37 |
| ▸ | PDE4C | Q08493 | 6/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 6/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30350700 | 1.00 | FFAR4 (0.40) | FFAR4PDE4APDGFRBPDGFRALRRK2 | |
| SCHEMBL2905574 | 0.97 | PDE4A (0.42) | FFAR4PDE4APDGFRBPDGFRALRRK2 | |
| SCHEMBL2414839 | 0.84 | PDE4A (0.42) | PDE4APDGFRBPDGFRAPDE4BPDE4C | |
| SCHEMBL2903176 | 0.81 | PDE4D (0.44) | PDE4ALRRK2PDE4BPDE4CPDE4D | |
| SCHEMBL2905403 | 0.81 | PDE4D (0.44) | PDE4ALRRK2PDE4BPDE4CPDE4D | |
| SCHEMBL26151328 | 0.81 | MCHR1 (0.46) | FFAR4PDE4APDGFRBPDGFRAPDE4B | |
| SCHEMBL2905855 | 0.80 | PDE4D (0.39) | PDE4ALRRK2PDE4BPDE4CPDE4D | |
| SCHEMBL6607678 | 0.79 | FFAR4 (0.43) | FFAR4PDE4APDGFRBPDGFRAPDE4B | |
| SCHEMBL441334 | 0.77 | KMT2A (0.39) | — | |
| SCHEMBL26151331 | 0.75 | FFAR4 (0.39) | FFAR4PDE4APDGFRBPDGFRAPDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107567443-B | Biaryl derivatives as GPR120 agonists | 株式会社LG化学 | 2023-04-28 | — | — | CN | disclosed |
| CN-115925679-A | Biaryl derivatives as GPR120 agonists | 株式会社LG化学 | 2023-04-07 | — | — | CN | disclosed |
| EP-3239143-B1 | BIARYL DERIVATIVE AS GPR120 AGONIST | LG CHEMICAL LTD (KR) | 2023-03-22 | — | — | EP | disclosed |
| US-20220135574-A1 | BIARYL DERIVATIVE AS GPR120 AGONIST | LG CHEM, LTD. (KR) | 2022-05-05 | — | — | US | disclosed |
| US-11261186-B2 | Biaryl derivative as GPR120 agonist | LG CHEM. LTD. (KR) | 2022-03-01 | — | — | US | disclosed |
| US-20170349594-A1 | BIARYL DERIVATIVE AS GPR120 AGONIST | LG CHEM, LTD. (KR) | 2017-12-07 | — | — | US | disclosed |
| EP-3239143-A2 | BIARYL DERIVATIVE AS GPR120 AGONIST | LG Chem, Ltd. (KR) | 2017-11-01 | — | — | EP | disclosed |
| EP-1692109-B1 | PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED DIARYLAMINE ANALOGS | MEMORY PHARM CORP (US) | 2010-08-18 | — | — | EP | disclosed |
| US-20090118270-A1 | PHOSPHODIESTERASE 4 INHIBITORS | TALAMAS FRANCISCO XAVIER | 2009-05-07 | — | — | US | disclosed |
| US-20070049611-A1 | Phosphodiesterase 4 inhibitors | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-01 | — | — | US | disclosed |
| US-20050222207-A1 | Phosphodiesterase 4 inhibitors, including N-substituted diarylamine analogs | MEMORY PHARMACEUTICAL CORPORATION | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049611-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE3B, PDE4B | FFAR4 1248/4885PDE4A 1/4885PDGFRB 543/4885 |
| US-20050222207-A1 | Phosphodiesterase 4 inhibitors, including N-substituted diarylamine analogs | PDE4A, PDE4B, PDE3B | FFAR4 572/4885PDE4A 1/4885PDGFRB 556/4885 |
| US-20220135574-A1 | BIARYL DERIVATIVE AS GPR120 AGONIST | GPR119, GLP1R, GIPR | FFAR4 24/4885PDE4A 1046/4885PDGFRB 672/4885 |
| US-20170349594-A1 | BIARYL DERIVATIVE AS GPR120 AGONIST | GPR119, GLP1R, GIPR | FFAR4 24/4885PDE4A 1046/4885PDGFRB 672/4885 |
| US-20090118270-A1 | PHOSPHODIESTERASE 4 INHIBITORS | PDE4A, PDE3B, PDE4B | FFAR4 1248/4885PDE4A 1/4885PDGFRB 543/4885 |
| US-11261186-B2 | Biaryl derivative as GPR120 agonist | GPR119, GPR88, FFAR1 | FFAR4 18/4885PDE4A 1093/4885PDGFRB 407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.